Day: November 15, 2021

Alba by Quotient: Revenues exceeded guidance; Achieved year-over year growth in Q2 FY 2022 of 15.9% Financial Position: Available cash & short-term investments of $141.8 million Business Update: Communication issued on November 9, 2021; providing a progress update on development and upcoming commercializationJERSEY, Channel Islands, Nov. 15, 2021 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its financial results for the second quarter of fiscal year 2022 and filed the quarterly report on Form 10-Q. Alba by Quotient – Revenues exceeded guidance and continued to drive double digit growth. Generated $9.2 million product sales in the second quarter, growing 15.9% over Q2 of FY 2021. Alba’s sales to OEM...

Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications. Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the “FT-200 Group”) and filed a provisional patent in connection to the composition of matter for the first molecule identified in the FT-200 Group. Continued to invest in best-in-class clinical infrastructure, with nine clinics currently in operation and nine locations under construction or about to commence construction. Commenced trading on the NASDAQ Global Select Market (“NASDAQ”) under the ticker symbol “FTRP”. As at September 30, 2021, Field Trip had approximately $88 million in unrestricted cash and cash equivalents...

– Grew Revenues to $44.8 Million, Up from $6.8 Million in Q3 2020 –– Achieved Record Profitability with Net Income of $23.7 Million, Up from a Net Loss of $4.8 Million in Q3 2020 – This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated August 16, 2021 to its short form base shelf prospectus dated August 12, 2021. TORONTO, Ontario and BROSSARD, Québec, Nov. 15, 2021 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ: BITF // TSXV: BITF), a global Bitcoin self-mining company, reported its financial results for the quarter ended September 30, 2021. All financial references are in US dollars. During Q3 2021, Bitfarms mined 1,051 Bitcoin (BTC), up 38% from 759 BTC in Q2 2021, and reduced the average cost of BTC production* to $6,900/BTC, down 23% from $9,000/BTC in Q2...

New Client SaaS Contracts Executed in Q3 2021 Represent the Highest Base Contract Revenue Ever Produced in a Single Quarter in Company History Total Digital Revenue Recognized in Q3 Increased 30% over Prior Quarter, and Now Represents 81% of Total Revenue, Up from 64% Last Year SaaS Recurring Revenue Up 25% Year over Year and Up 15% over Q2 Non-SaaS Digital Revenue Increased 144% over Q2 and 42% Year over Year Combined Revenue Up More than 21% over Q2 Launched Professional Sports Vertical, Partnering with Pittsburgh Penguins for Verb Interactive Video Sales Enablement Platform to Drive Ticket Sales and Fan Engagement; Expects More Professional Sports Team Announcements to FollowNEWPORT BEACH, Calif. and SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the...

Company shows significant quarter-over-quarter and year-over-year growth across revenue, production, and fleet size, as well as expanding land stewardship goalsWind tower components for Greenbacker’s RoxWind assetGreenbacker COO Matt Murphy (center) and team members welcomed the arrival of towers and turbines for RoxWind—GREC’s 15.3-MW wind project in Roxbury, ME.NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) — Greenbacker Renewable Energy Company LLC (“Greenbacker,” “GREC,” or the “Company”), a leading owner and operator of sustainable infrastructure and energy efficiency projects, recently announced financial results for the three-month period ended September 30, 2021.1 A number of positive trends were evident, both on a quarter-over-quarter basis (comparing the third quarter of 2021 with the second quarter...

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the third quarter of 2021 and recent corporate updates. “In the third quarter, we successfully completed our convertible note financing of $15 million that provided us with the necessary proceeds to continue our advancement of our lead clinical trial programs,” said Dr. Lynn Kirkpatrick, CEO of Ensysce. “As previously announced, we commenced our second study of our TAAP opioid, PF614, in early September, and through this study, we aim to demonstrate the correlation between PF614 to Oxycontin, and how Ensysce can begin...